ARK Investment Management LLC Has $6.56 Million Stock Position in COMPASS Pathways plc (NASDAQ:CMPS)

ARK Investment Management LLC lowered its stake in COMPASS Pathways plc (NASDAQ:CMPS) by 13.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,736,202 shares of the company’s stock after selling 268,923 shares during the quarter. ARK Investment Management LLC owned approximately 2.54% of COMPASS Pathways worth $6,563,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Sio Capital Management LLC increased its position in shares of COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after acquiring an additional 621,222 shares during the last quarter. Rosalind Advisors Inc. increased its position in shares of COMPASS Pathways by 6.5% in the third quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock valued at $4,923,000 after acquiring an additional 47,423 shares during the last quarter. Polar Asset Management Partners Inc. increased its position in shares of COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after acquiring an additional 258,000 shares during the last quarter. Acuta Capital Partners LLC acquired a new position in COMPASS Pathways during the third quarter worth approximately $2,435,000. Finally, Walleye Capital LLC acquired a new position in COMPASS Pathways during the third quarter worth approximately $2,126,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Price Performance

COMPASS Pathways stock opened at $3.65 on Wednesday. COMPASS Pathways plc has a 12 month low of $3.16 and a 12 month high of $12.75. The stock’s 50 day moving average is $4.07 and its 200-day moving average is $5.30. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $249.74 million, a price-to-earnings ratio of -1.66 and a beta of 2.28.

Analysts Set New Price Targets

A number of brokerages have weighed in on CMPS. Maxim Group lowered their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Finally, HC Wainwright lowered their price target on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $30.60.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.